NCT03470454View on ClinicalTrials.gov

Contrast Nephropathy in Type 2 Diabetes

CompletedOBSERVATIONAL

Enrollment

40

Participants

Timeline

Start Date

July 1, 2018

Primary Completion Date

September 30, 2018

Study Completion Date

November 30, 2018

Conditions

Kidney Function Affection Upon Exposure to RadiocontrastDiabetesMicroalbuminuria

Interventions

DRUG

Linagliptin Oral Tablet

Linagliptin for blood glucose control

Trial Locations (2)

Unknown

Faculty of medicine Fayoum univesity, Al Fayyum

Fayoum University, Al Fayyum

Sponsors

Collaborators (1)

Boehringer Ingelheim

All Listed Sponsors

collaborator

Boehringer Ingelheim

INDUSTRY

lead

Fayoum University

OTHER

NCT03470454 - Contrast Nephropathy in Type 2 Diabetes | Biotech Hunter | Biotech Hunter